IGG Aktie

 

LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS)......

LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS)......

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal......

The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields. Both formulations tested induced strong systemic antibody response in serum (IgG) as well as locally in the......

The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields. Both formulations tested induced strong systemic antibody response in serum (IgG) as well as locally in the......

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody FcRn-targeting competition. Up to 84% reduction of total IgG was observed with a median......

- Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing Q4W or Q8W subcutaneous (SC) VRDN-003 in active and chronic TED, progressing as planned and on track for topline data for both trials in the first half of 2026 - - Proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter of 2025 for VRDN-006, an Fc fragment inhibitor of the neonatal Fc receptor (FcRn) - - VRDN-008, a bispecific FcRn inhibitor with an extended half-life, expected to have additional preclinical data in 2025 with an Investigational New Drug (IND) submission planned for year-end 2025 - - Viridian appoints Radhika Tripuraneni, M....

Shares | Ratings | Target prices (HK$)TENCENT(00700.HK) | Outperform | 468 NTES-S(09999.HK) | Outperform | 180 KUAISHOU-W(01024.HK) | Outperform | 66 BILIBILI-W(09626.HK) | Outperform | 188 TME-SW(01698.HK) | Outperform | 52 NETEASE MUSIC(09899.HK) | Outperform | 150 IGG(00799.HK) | Outperform | 4.16 BIDU-SW(09888.HK) | Outperfo......

- Veligrotug, with recent positive phase 3 topline data in both active and chronic thyroid eye disease (TED), has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with less drug and fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 - - REVEAL-1 and REVEAL-2, phase 3 clinical trials for subcutaneous (SC) VRDN-003 in active and chronic TED respectively, are currently dosing patients; topline data for both trials, which are evaluating VRDN-003 dosed Q4W or Q8W, is on track for the first half of 2026 - - Investigational New Drug (IND) submitted in December 2024 for VRDN-006, an Fc fragment inhibitor of the neonatal Fc receptor (FcRn); proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter of 2025 - - VRDN-008, a bispecific FcRn inhibitor with an extended half-life, progressing with preclinical studies as planned; additional preclinical data expected in 2025 with an ...

Lund, Sweden, 17 December 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS. Data from the 15-HMedIdeS-09 study demonstrated that severe GBS patients treated with a...

Lund, Sweden, 7 October 2024. Hansa Biopharma AB, (“Hansa” or the “Company”) (Nasdaq Stockholm: HNSA), today announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity and redosing potential. In the NICE-01 trial, HNSA-5487 demonstrated rapid and highly robust reduction of IgG levels by more than 95 percent within a few hours post treatment. In a 12-month follow up analysis IgG levels returned to normal range six months after initial...

Das Instrument I91 KYG6771K1022 IGG INC. DL-,0000025 EQUITY wird cum Dividende/Zinsen gehandelt am 09.09.2024 und ex Dividende/Zinsen am 10.09.2024 The instrument I91 KYG6771K1022 IGG INC. DL-,0000025 EQUITY has its pre-dividend/interest day on 09.09.2024 and its ex-dividend/interest day on 10.09.2024...

MSCI announced the results of the quarterly index review, and the changes will take place as of the close of market on 30 August. Of which, the MSCI Hong Kong Small Cap Index added DFI Retail Group, ENVISION GREEN (01783.HK), HAO TIAN INTL (01341.HK), SANERGY GROUP (02459.HK) and TIME INTERCON (01729.HK), and deleted C-MER MEDIC......

Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

Lund, Sweden, 21 May, 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announced data featuring imlifidase will be presented at the American Transplant Congress (ATC), the joint annual meeting of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (ATS). Imlifidase is Hansa's unique antibody-cleaving enzyme that specifically targets IgG and inhibits IgG-mediated immune response.[1] Søren Tulstrup, CEO and President, Hansa Biopharma, said: “ATC is a valuable opportunity for Hansa to share the latest science and data around...